Sickle Cell Disease

Sickle cell disease is a group of inherited disorders caused by sickle hemoglobin (HbS), which polymerizes when deoxygenated and deforms red blood cells into a rigid, sickle shape. The resulting chronic hemolytic anemia and recurrent vaso-occlusion produce painful episodes and progressive organ damage. It is one of the most common and clinically significant structural hemoglobinopathies.

Definition

Sickle cell disease comprises inherited conditions in which sickle hemoglobin (resulting from a substitution of valine for glutamic acid at the sixth position of the beta-globin chain) polymerizes on deoxygenation, causing red-cell sickling, chronic hemolytic anemia, and recurrent vaso-occlusion.

Scope

This topic covers the molecular basis of HbS polymerization, the spectrum of genotypes (homozygous HbSS and compound heterozygous states such as HbSC and HbS/beta-thalassemia), the principal disease mechanisms of hemolysis and vaso-occlusion, and the epidemiology shaped by malaria selection. It is a reference entry on the disorder and does not provide individualized clinical management.

Core questions

• How does a single beta-globin substitution lead to red-cell polymerization and sickling?
• How do hemolysis and vaso-occlusion each contribute to acute and chronic complications?
• Why does disease severity vary across genotypes and with fetal hemoglobin levels?

Key concepts

• Sickle hemoglobin (HbS) and the beta6 Glu→Val substitution
• Deoxygenation-dependent HbS polymerization
• Vaso-occlusion
• Chronic hemolytic anemia
• Compound heterozygosity (HbSC, HbS/beta-thalassemia)
• Fetal hemoglobin (HbF) as a modifier of severity
• Sickle cell trait (heterozygous carrier state)

Mechanisms

The disease originates in a single point mutation that substitutes valine for glutamic acid at position 6 of the beta-globin chain, producing sickle hemoglobin. When HbS is deoxygenated it polymerizes into rigid fibers that distort the red cell into the characteristic sickle shape and reduce its deformability. These cells hemolyze prematurely, producing chronic anemia, and adhere abnormally to the endothelium and to one another, obstructing the microcirculation. The resulting vaso-occlusion drives the acute painful episodes and ischemic organ injury that define the clinical course. Disease expression is modified by the amount of fetal hemoglobin (which inhibits polymerization), by co-inherited alpha-thalassemia, and by the specific genotype, so that compound heterozygous states differ in severity from homozygous HbSS disease.

Clinical relevance

Sickle cell disease is a leading cause of inherited hemolytic anemia and a frequent subject of newborn screening, making familiarity with its mechanisms important for interpreting hemoglobin analysis and anemia evaluation. This entry summarizes the disorder for reference and educational purposes and is not a basis for individual diagnostic or treatment decisions.

Epidemiology

Sickle hemoglobin reaches high frequency in regions where malaria has been endemic—sub-Saharan Africa in particular, as well as parts of the Mediterranean, the Middle East, and the Indian subcontinent—because carriers gain partial protection against severe malaria. Migration has distributed the disorder worldwide, and Weatherall and colleagues characterize it as part of an emerging global health burden with hundreds of thousands of affected births each year.

History

In 1949 Pauling and colleagues described sickle cell anemia as a molecular disease, the first time a clinical illness was attributed to an abnormal protein, and Ingram subsequently identified the responsible single amino-acid substitution. These findings made sickle hemoglobin a foundational example in molecular medicine. Later work elaborated the polymerization mechanism and the modifying role of fetal hemoglobin, and the recognition of malaria selection explained the high frequency of the sickle allele.

Key figures

• Linus Pauling
• Vernon Ingram
• Martin Steinberg
• Russell Ware
• Frédéric Piel

Seminal works

• piel-2017
• ware-2017
• weatherall-2010

Frequently asked questions

What causes red cells to sickle in sickle cell disease?

Sickle hemoglobin polymerizes into rigid fibers when it gives up oxygen, distorting the red cell into a sickle shape that is fragile and prone to obstructing small blood vessels.

Is sickle cell trait the same as sickle cell disease?

No. Sickle cell trait is the heterozygous carrier state, in which a person inherits one sickle and one normal beta-globin gene and is generally healthy, whereas sickle cell disease refers to the symptomatic genotypes such as homozygous HbSS or compound heterozygous states.